

DX-1900

FOUNDED 2017

The Company is an advanced manufacturing company offering customized medical devices. With the vision of giving the world a better reason to smile, the Company has created the most competitive clear aligner treatment currently offered on the market.

The Company has a manufacturing facility in Australia, housing fit-for-purpose 3D printers and robotic cells in a clean room. With 3D printing thought leaders hand-picked from around the world (spanning some of the very first marketers and innovators in 3DP), the Company has already set regulatory standards for clear aligner treatments in Australia. The Company boasts a customer base of over 400 dentists leveraging their medical devices to improve patient care.

The Company plans to continue to grow quickly and consolidate its position in the Australian clear aligner market, plus continue with joint ventures and distribution agreements in China, India, Singapore and Europe. The Company recently signed an MOU to begin regulatory approval and production in China. Success in the Australian market will be a stepping stone to strong global growth.

COMPANY OBJECTIVE



HEADQUARTERS
Australia



OF EMPLOYEES
35

Management	02	
Sales & Marketing	07	
Accounting/Finance	02	
Manufacturing	09	
Administrative	02	
Professional Services	02	
Part-Time Employees	06	
Contractors	04	
Advisory Committee	04	

PRODUCTS AND SERVICES

Professional 3D Printing Solutions & Services

- A phased approach to custom-made invisible aligners with no need for refinement
- High speed turnaround

Hardware

- 100% digital designs
- Whitening and acceleration devices
- Scanners


Software as a Service (SaaS)

- Customized CX portal for end-to-end patient treatment
- Ease of use doctor to patient communication tools

Materials

- Customized proprietary polymers
- Dedicated packaging materials with a strong brand

FINANCIALS 2017-2020(E)



Description* (\$M)	2016/17	2017/18	2018/19	2019/20(E)
Revenue	\$0.00	\$0.53	\$1.13	\$3.46
Gross Profit	\$0.00	\$0.43	\$0.36	\$1.80
SG&A	(\$0.79)	(\$3.16)	(\$3.67)	(\$4.73)
EBITDA	(\$0.79)	(\$2.73)	(\$3.31)	(\$2.93)

*financial period is July to June

% REVENUE BY SERVICE TYPE



INVESTMENT CONSIDERATIONS

- Best in Class Clinical Outcomes for Clear Aligner Treatments** - The Company's phased approach to treatment ensures compliance, resulting in no need for patient refinements. The Company's clear aligners fit better, are more comfortable, and boast superior quality compared to the competition. The robotics cells used in their process to trim the gingival gum line is more accurate. Furthermore, the Company's clear aligner treatments are delivered in **under 7 days** vs. competitors at 6 to 8 weeks.
- Setting a Standard** - The Company led the Therapeutics Goods Administration (TGA) process that will tighten regulations governing customized medical devices in Australia and around the world. The Company is ahead of the curve with regards to regulatory and ISO compliance. Prepared for increased regulatory oversight in the dental market, the Company is well positioned in 2020.
- Global Growth Strategy** - In Australia & Europe, the Company continues to consolidate their market position with increased branding and partnerships with the largest dental chains. In addition, the Company is leveraging strategic relationships in Asia to commence regulatory approval, distribution, and production of their clear aligners in the Chinese market.
- SaaS Portal for Patient Satisfaction** - The Company has developed an end-to-end CX user portal to improve the patient journey. The customized CX portal improves lead conversion to clear aligner sales, plus creates more efficient communication between patients and dentists about treatment plans.
- Talented Team** - The Company's technical team is sourced from around the world, and sales teams are established in every Australian state. The sales team has signed over 400 dentists to offer its clear aligner treatments, and the Company's team overall boasts experience in Asia, the US, Israel, and Europe.

PATENTS & INTELLECTUAL PROPERTY

Phased Treatment Approach

Robotic Trimming

Bespoke Customer Experience SaaS Platform

Digitized Production Facility, Replicable Medical Grade Clean Room Environment



TOTAL CHANNEL PARTNERS 2016-2020(E)

FY 2017/18	50	
FY 2018/19	225	
FY 2019/20	408	out of 500


GOLD CHANNEL PARTNERS 2016-2020(E)

FY 2017/18	2	
FY 2018/19	28	
FY 2019/20	88	out of 100

END USER VERTICALS



VENDORS & PARTNERS



AWARDS & RECOGNITION



CERTIFICATIONS



NEXT STEPS

To learn more about company DX-1900 please execute NDA and send to Madeline Bleiweiss. Our team will follow up with a mutually executed NDA and provide an introduction to the company's CEO.



Start NDA Now

Madeline Bleiweiss

Asset Listing